Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04206553 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT04206553 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 106 participants.
The verdict
NCT04206553, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60). The study is looking at several other research questions, including: * Side effects that may be experienced by people taking dupilumab * How dupilumab works in the body and affects the body * How dupilumab affects quality of life * How much dupilumab is present in the blood * To see if dupilumab works to wean the patient off oral corticosteroids
Interventions
- DRUG dupilumab
- DRUG Matching Placebo
- DRUG Oral corticosteroids (OCS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2025-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04206553
The ClinicalTrials.gov registry entry for NCT04206553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dupilumab is the first listed.
NCT04206553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04206553 about?
NCT04206553 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid". The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and...
What is the current status of trial NCT04206553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2020-10-28. Estimated completion is 2025-01-05.
What interventions are being tested in trial NCT04206553?
The interventions under investigation include: dupilumab (DRUG), Matching Placebo (DRUG), Oral corticosteroids (OCS) (DRUG).
Who is sponsoring clinical trial NCT04206553?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.